Author

Francois E. Wilhelm

Observed names: F Wilhelm, F. E. Wilhelm, F. Wilhelm, FE Wilhelm, Francois E Wilhelm, Francois Wilhelm, François Wilhelm, Wilhelm, Francois E.

Observed institutions: University of California, Riverside, Indiana University Health, Roswell Park Comprehensive Cancer Center, Houston Methodist, Inserm, University of California, Los Angeles, Cornell University, University of Alabama at Birmingham, Massachusetts General Hospital, Hôpital Lariboisière, Onconova Therapeutics (United States), Immunomedics (United States), University of Colorado Cancer Center, Weill Cornell Medicine, Vanderbilt-Ingram Cancer Center, Akros Pharma Inc. (United States), Janssen Research & Development (United States), University of Colorado Anschutz

OpenAlex ID: A5033199189

Effectiveness of Inhibition of Cholesteryl Ester Transfer Protein by JTT-705 in Combination With Pravastatin in Type II Dyslipidemia

2005 · Jan Albert Kuivenhoven, Greetje J. de Grooth, et al. · The American Journal of Cardiology · 170

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

2016 · Guillermo Garcia-Manero, Pierre Fenaux, et al. · The Lancet Oncology · 169

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

2015 · B.H. O'Neil, A.J. Scott, et al. · Annals of Oncology · 130

PDF

Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma

2015 · Bishoy Faltas, David M. Goldenberg, et al. · Clinical Genitourinary Cancer · 106

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

2014 · Daniel W. Bowles, Jennifer R. Diamond, et al. · Clinical Cancer Research · 75

Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

2014 · Lewis R. Silverman, Peter Greenberg, et al. · Hematological Oncology · 70

PDF

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes

2013 · Rami S. Komrokji, Azra Raza, et al. · British Journal of Haematology · 58

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

2012 · Wen Wee Ma, Wells A. Messersmith, et al. · Clinical Cancer Research · 54

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na

2011 · Mahesh Seetharam, Alice C. Fan, et al. · Leukemia Research · 54

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na

2012 · Matthew J. Olnes, Aarthie Shenoy, et al. · Leukemia Research · 43

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

2015 · B.H. O'Neil, A.J. Scott, et al. · Annals of Oncology · 38

PDF

The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

2013 · Ryan T. Anderson, Stephen B. Keysar, et al. · Molecular Cancer Therapeutics · 31

Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia

2006 · David H. Henry, Lucio N. Gordan, et al. · Current Medical Research and Opinion · 26

Biochemical characterization of positive cooperativity in the binding of 1 alpha, 25-dihydroxyvitamin D3 to its chick intestinal chromatin receptor.

1985 · F Wilhelm, A W Norman · Journal of Biological Chemistry · 23

6-Fluoro-vitamin D3: A new antagonist of the biological actions of vitamin D3 and its metabolites which interacts with the intestinal receptor for 1α,25(OH)2-vitamin D3

1984 · Francois Wilhelm, William G. Dauben, et al. · Archives of Biochemistry and Biophysics · 22

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

2014 · Guillermo Garcia-Manero, Pierre Fenaux, et al. · Blood · 21

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

2013 · M Roschewski, M Farooqui, et al. · Leukemia · 21

Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.

2013 · Takao Ohnuma, Deborah Lehrer, et al. · PubMed · 20

Cooperativity in the binding of 1α,25‐dihydroxyvitamin D3 to the chick intestinal receptor

1984 · Francois Wilhelm, Anthony W. Norman · FEBS Letters · 19

PDF

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

2016 · B.H. O'Neil, A.J. Scott, et al. · Annals of Oncology · 16

PDF

Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na

2010 · Mahesh Seetharam, Mai Tran, et al. · Blood · 16

Specific binding of 24R,25-dihydroxyvitamin D3 to chick intestinal mucosa: 24R,25-dihydroxyvitamin D3 is an allosteric effector of 1,25-dihydroxyvitamin D3 binding

1986 · François Wilhelm, F.Patrick Ross, et al. · Archives of Biochemistry and Biophysics · 16

Biological activity assessment of the 26,23-lactones of 1,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 and their binding properties to chick intestinal receptor and plasma vitamin D binding protein

1984 · Francois Wilhelm, Eberhard Mayer, et al. · Archives of Biochemistry and Biophysics · 15

Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

2015 · Aditya Bardia, Linda T. Vahdat, et al. · Journal of Clinical Oncology · 12

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

2015 · Aaron James Scott, Bert H. O'Neil, et al. · Journal of Clinical Oncology · 12

Works count: 105

Citation count: 1,416

H-index: 19

I10-index: 28